1
levels. In agreement with previous reports, U-2 OS cells stably expressing HA-RNF169 displayed 1 approximately 50% less cells with more than ten 53BP1 foci, and had fewer IRIFs per nucleus ( Figures 3A and  2 B, compare white bars). Treatment of these cells with harmine resulted in significant increase of 53BP1 foci 3 formation although it was not rescued to the control levels ( Figures 3A and B, compare black bars) . 4
Interestingly, HA-RNF169 foci formation was decreased by approximately 30% in harmine-treated cells 5 compared to controls (Figures 3C and D) . Since the binding between RNF169 and DYRK1A was unaffected by 6 harmine ( Figure 3E) , it is likely that increased formation of 53BP1 IRIFs upon harmine treatment is due to a 7 reduced recruitment of HA-RNF169 to DSBs in the DYRK1A-inhibited cells. Together, these results show that 8 RNF169 and DYRK1A interact at the endogenous levels in human cells, and that DYRK1A is a positive 9 regulator of RNF169 that limits the accumulation of 53BP1 at the DSB sites. 10 11 DYRK1A phosphorylates functionally important Ser368 and Ser403 residues in RNF169. 12
The RNF169 protein sequence contains two predicted DYRK1A consensus sites R-x(xx)-S-P (Himpel 13 et al., 2000) . These sites, S386 and S403, are located within a highly conserved amino acid region in RNF169 14 that has no known function ( Figure 4A ). Importantly, in vivo phosphorylation of these sites in the native human 15 RNF169 is reported in the PhosphoSitePlus proteomics database (Hornbeck et al., 2012) . To determine 16 whether DYRK1A can phosphorylate S368 or S403 in RNF169, we performed in vitro kinase assays using HA-17 tagged RNF169, S386A-or S403A-or S368A/S403A-RNF169 transiently expressed in HEK293T cells and 18 immunoprecipitated, as substrates for recombinant purified DYRK1A. To avoid any co-precipitating kinase 19 activity, HA-RNF169 immunoprecipitates were heat-inactivated at 65°C for 10 minutes prior to incubation with 20 DYRK1A. As predicted, we observed that RNF169 was phosphorylated by DYRK1A, and that each of the 21 S368A or S403A mutations decreased the RNF169 phosphorylation while the mutation of both sites further 22 reduced the RNF169 phosphorylation ( Figure 4B and C). It should be noted that some residual 23 phosphorylation could be detected in the S368A/S403A (RNF169-AA) mutant. This could be due to a presence 24 of additional, non-canonical DYRK1A phosphorylation site(s) in RNF169, or because of the contaminating 25 kinase activity in our recombinant DYRK1A preparation.
To further characterize the functional significance of DYRK1A phosphorylation sites in RNF169, we 1 analyzed localization of 53BP1 and RNF169 after γ-radiation-induced DNA damage in U-2 OS cell lines stably 2 expressing either wild type HA-RNF169, or non-phosphorylatable S368A/S340A (RNF169-AA) mutant. 3 Interestingly, we observed approximately two-fold higher number of cells with more than ten 53BP1 foci in 4 RNF169-AA-expressing cells compared to the wild type HA-RNF169 cell line ( Figures 5A and B) . The number 5 of 53BP1 foci per nucleus was also significantly higher in the cells expressing RNF169-AA than in the wild type 6 HA-RNF169 cells, indicating that non-phosphorylatable RNF169 mutant inhibits accumulation of 53BP1 at DSB 7 sites to a significantly lesser extent than the wild type RNF169 ( Figure 5C ). Of note, the 53BP1 IRIF formation 8 was only partially rescued in the RNF169-AA U-2 OS cell line and did not reach the control levels, similar to the 9 effect observed in harmine-treated HA-RNF169 overexpressing cells ( Figure 3B ). However, while harmine 10 treatment decreased the HA-RNF169 IRIF formation ( Figure 3D ), the RNF169-AA mutant showed only a 11 slightly reduced recruitment to DSBs compared to the wild type RNF169 ( Figure 5D and E). We also tested 12 whether a phospho-mimetic mutation of the S368 and S403 to aspartic acid residues in RNF169 can rescue 13 the 53BP1 IRIF inhibition. However, the phenotype of RNF169-DD mutant was very similar to RNF169-AA 14 ( Figure S3A , B and C). It is possible that S368D/S403D mutation does not accurately represent a constitutively 15 phosphorylated state of the protein but instead disrupts the same function as in case of the S368A/S403A 16 mutation. Next, we tested whether any known functions of RNF169 are impacted by mutation of the DYRK1A 17 phosphorylation sites. Previous studies found that the recruitment of RNF169 at the DSB sites and 18 displacement of 53BP1require ubiquitin-binding MIU domain of RNF169 that recognizes polyubiquitilated chromatin at the site of damage (Chen et al., 2012; Hu et al., 2017; Poulsen et al., 2012) . Both 20 the RNF169-AA and RNF169-DD mutants were able to bind polyubiquitin chains similar to the wild type 21 RNF169, further supporting our conclusion that S368 and S403 sites do not play a role in RNF169's 22 accumulation at the DSB sites ( Figure S3E ). Furthermore, mutations of these sites did not affect the interaction 23 with ubiquitin-specific protease USP7 that has been shown to be important for RNF169 function in DNA repair 24 (An et al., 2017) ( Figure S3F ). Therefore, our data presented above support the conclusion that the intact S368 25 and S403 sites in RNF169, together with the DYRK1A kinase activity, are required for RNF169 to fully exert its ability to limit the recruitment of 53BP1 at the DSB sites after γ-radiation, through a mechanism unrelated to 1 recognition of the ubiquitylated chromatin or USP7 binding by RNF169. 2 3 Loss of DYRK1A impairs the DSB recruitment of 53BP1 independent of RNF169 4
To further investigate the effects of DYRK1A loss on 53BP1 and RNF169 function, we depleted 5 DYRK1A in U-2 OS cells using shRNA, and analyzed recruitment of Consistent with the phenotypes observed upon inhibition of DYRK1A or mutation of the DYRK1A 7 phosphorylation sites in RNF169, we observed an approximately 10% decrease of the HA-RNF169 IRIF 8 formation in shDYRK1A-U-2 OS cells compared to controls ( Figure S4A ). However, the recruitment of 53BP1 9 in DYRK1A-depleted U-2 OS cells was also significantly decreased when compared to controls ( Figure S4B) . 10 Furthermore, transient knockdown of DYRK1A in U-2 OS cells using two different siRNA oligos did not 11 significantly affect the 53BP1 DSB recruitment (data not shown). Since this apparent discrepancy could be due 12 to a residual DYRK1A expression in the siRNA or shRNA-treated cells, we generated U-2 OS cell lines 13 harboring frame-shift mutations in DYRK1A gene by CRISPR-Cas9 gene editing approach (Cong et al., 2013) . 14 Of note, the Cell Line Encyclopedia data show a partial loss of chromosome 21 harboring the DYRK1A gene in 15 U-2 OS (Barretina et al., 2012) . Using DNA FISH and immunoblotting, we confirmed presence of a single copy 16 of the DYRK1A gene in U-2 OS cells ( Figure S4A ). To reduce the possibility of any off-target effects, we 17 transiently expressed Cas9 endonuclease and DYRK1A-specific guiding RNA in U-2 OS cells and isolated 18 individual single-cell clones that were screened for loss of DYRK1A protein expression using WB. Two 19 independent U-2 OS DYRK1A-KO clones were expanded and validated by WB and genomic DNA sequencing 20 ( Figures 6A and S5 ). Furthermore, we confirmed a significant loss of DYRK1A kinase activity in the U-2 OS 21 DYRK1A-KO cell lines using a whole cell extract in vitro kinase assay with purified LIN52 as substrate, and a 22 phosphospecific antibody against LIN52-S28 site for detection ( Figure 6B ). 23
In agreement with our observation using shDYRK1A cells, both U-2 OS DYRK1A-KO cell lines 24 displayed a decrease in DSB recruitment of HA-RNF169 (transiently expressed) although the extent of this 25 effect varied between the two DYRK1A-KO clones ( Figure 6C and D). Furthermore, we observed a 50% decrease in the number of 53BP1 IRIFs per nucleus, resulting in significantly fewer cells with more than ten 1 53BP1 foci when compared to control cell lines ( Fig. 6E and F). To address the mechanism of this 53BP1 2 recruitment defect, we analyzed the expression of several damage response markers during DNA repair. As 3 shown in Figure S6A , there was no change in the induction of p53 or γH2AX in the DYRK1A-KO cells 4 compared to control. Interestingly, protein levels of 53BP1 and BRCA1 appeared to be increased in the 5 DYRK1A-KO cells compared to control whereas the expression of RNF169 was unchanged ( Figure S6A ). 6
Furthermore, loss of DYRK1A in U-2 OS cells did not affect the DNA damage checkpoint, as evident by 7 accumulation of cells in G1 and G2 phases after γ-radiation ( Figure S6B ). Accumulation of γH2AX and 8 ubiquitylation of histones at the DNA damage sites also appeared to be unchanged in the DYRK1A-KO cells 9 compared to controls ( Figure S7A and B). Since accumulation of both 53BP1 and BRCA1 at the DSB sites 10 requires the activity of RNF168 and RNF8 E3 ubiquitin ligases, we also analyzed the recruitment of BRCA1 in 11 these cells and found it similar ( Figure S7C ). Therefore, we concluded that decreased recruitment of 53BP1 to 12 the damage sites was likely not because of abnormal DNA damage signaling or histone ubiquitylation in the 13 DYRK1A-KO cells. 14 Since U-2 OS cells could have intrinsically reduced DYRK1A expression resulting from loss of one copy 15 of the DYRK1A gene, we sought to further validate our findings described above using a different cell line. To 16 do so, we knocked out Dyrk1a expression in mouse NIH-3T3 fibroblasts using CRISPR-Cas9 approach (Figure 17 S5D). We first determined that the number of 53BP1 foci in NIH-3T3 cell peaked after 1h post γ-irradiation and 18 started to decrease at 3h, and that 3 Gy was the optimal dose to observe distinct nuclear foci (data not shown). 19
Using these experimental conditions, we again observed an impaired 53BP1 IRIF formation in two independent 20 single-cell derived NIH-3T3 Dyrk1a-KO clones compared to control cells ( Figure 6G ). Interestingly, while 21 approximately 80% of both the control and Dyrk1a-KO NIH-3T3 cells contained more than 10 53BP1 foci at 1h 22 post γ-irradiation, initial recruitment of 53BP1 was impaired by loss of Dyrk1a because the average number of 23 foci per nucleus was significantly lower in the Dyrk1a-KO cells compared to control ( Figure 6G ). At 3h post γ-24 irradiation, the number of foci per nucleus decreased by approximately 50% in both the control and Dyrk1a-KO 25 cell lines, indicative of a similar rate of resolving the lesions and removal of 53BP1 foci in these cells lines.
To further confirm that the phenotype of the DYRK1A-KO U-2 OS cells was specific to a loss of 1 DYRK1A protein and kinase activity, we re-introduced either active DYRK1A, or kinase inactive K188R-2 DYRK1A mutant, into one of our knockout clones. Indeed, we observed that expression of the wild-type 3 DYRK1A, but not the kinase inactive mutant, resulted in a complete rescue of the 53BP1 IRIF defect in these 4 cells ( Figures 7A and B ). We also investigated whether the effect of DYRK1A loss on 53BP1 is mediated by 5 RNF169. Interestingly, unlike DYRK1A overexpressing cells ( Figure 2H ), knockdown of RNF169 in DYRK1A-6 KO U-2 OS cells resulted in only a partial rescue of the 53BP1 recruitment to the DSB sites, and the RNF169-7 depleted DYRK1A-KO cells still showed significantly lower 53BP1 IRIF formation when compared to 8 corresponding control cell lines ( Figure 7D ). This result suggests that the 53BP1 recruitment defect in the 9 absence of DYRK1A is not likely due to a more efficient displacement by RNF169. Together, these results 10 support the conclusion that DYRK1A regulates the initial recruitment of 53BP1 to damaged chromatin both in 11 the RNF169-dependent and independent manner. 12 13
Loss of DYRK1A promotes the HRR and DNA repair 14
Previous studies demonstrated the role of 53BP1 in suppressing the HR-mediated DNA repair by 15 protecting the DNA ends around the site of damage from resection (Canny et al., 2018; Durocher and Pelletier, 16 2016) . Since loss of DYRK1A decreased accumulation of 53BP1 at the DSB sites, we investigated its effect on 17 the DNA repair pathway determination using the control and DYRK1A-KO U-2 OS cell lines stably expressing 18 the direct repeat (DR) GFP reporter of the HR repair (Pierce et al., 1999) . In this model system, a DSB is 19 generated by cleavage of the non-functional GFP gene fragment by I-SceI restriction nuclease. The break is 20 then repaired either by NHEJ, resulting in no GFP protein expression, or by HRR, in which case a fluorescent 21 protein is produced ( Fig. 8A ). Consistent with reduced recruitment of 53BP1 to DSBs in the DYRK1A-KO cells, 22
we observed approximately two fold increase in GFP-positive cells formation after I-SceI expression in these 23 cells compared to control U-2 OS cells ( Fig. 8B) . 24
Targeting DNA repair processes is an important strategy for anti-cancer therapy (Brown et al., 2017) . treated with inhibitors of anti-cancer drugs inhibiting poly (ADP-ribose) polymerases (PARP), such as olaparib, 1 making these drugs especially efficient in cancers with mutations in the HR repair pathway (Lin and Kraus, 2 2017; Pommier et al., 2016) . In HR-proficient cancer cells, olaparib can potentiate the effect of other DNA 3 damaging drugs (Griguolo et al., 2018; McCann, 2018) , possibly by attenuating the efficiency of HR-mediated 4 repair as it was shown in U-2 OS cells (Jelinic and Levine, 2014) . Factors that mediate cancer cell resistance 5 to PARP inhibitors are not fully understood; therefore, we were interested to see if loss of DYRK1A can 6 influence the cell response to olaparib by promoting HR ( Figure 8C ). Consistent with previous data, in case of 7 control DR-GFP U-2 OS cells, olaparib caused a significant inhibition of the HR-mediated repair efficiency and 8 decrease of cell number as compared to vehicle-treated cells. However, DYRK1A-KO cells appeared to be 9 more refractory to olaparib effect than the control cells although the extent of PARP inhibition was similar in 10 both cell lines ( Figure 8C -F). Therefore, loss of DYRK1A in cancer cells could increase resistance to PARP 11 inhibitors or other DNA damaging treatments by facilitating the HR-mediated repair. 12
In order to determine whether different DYRK1A mRNA expression levels in cancer can be associated 13 with particular clinical outcomes, we searched publically available cancer TCGA datasets. We found that 14 expression of DYRK1A was significantly reduced in cancer samples compared to normal tissue in several 15 cancer types, including invasive breast carcinoma (data not shown). Interestingly, while DYRK1A mRNA 16 expression had no significant association with the outcomes in the entire breast cancer patient's dataset, low 17 expression of DYRK1A significantly correlated with decreased survival in the group of patients treated with γ-18 irradiation ( Figure 8G ). Similar results were observed in radiation-treated lung adenocarcinoma patient cohort 19 (data not shown), indicating that low DYRK1A expression could be a negative prognostic marker for predicting 20 the outcomes of radiation therapy in certain types of cancer. 21
22
Discussion 1 DYRK1A gene copy number changes have deleterious effects on prenatal and early postnatal brain 2 development and have been linked to neurodegenerative disease and cancer (Abbassi et al., 2015; Dierssen 3 and de Lagran, 2006; Tejedor and Hammerle, 2011) . Since even subtle changes in DYRK1A levels appear to 4 deregulate its function, it is possible that some effects of DYRK1A gene imbalance could be mediated by 5 perturbation of DYRK1A interaction networks. Our data presented here offer an insight into a complexity and 6 functional diversity of the protein-protein interactions that involve this remarkable protein kinase in human cells. 7
Currently, the BioGrid protein interaction network database lists 80 DYRK1A-interacting proteins, 8 mostly identified by high-throughput affinity-capture mass spectrometric analyses performed in HEK293T cells 9 (Chatr-Aryamontri et al., 2015) . Using sensitive MudPIT proteomic approach (Florens and Washburn, 2006; 10 Swanson et al., 2009) , we identified 120 proteins specifically detected in at least two out of four biological 11 replicate analyses of DYRK1A immunoprecipitates from human T98G cells, including 98 proteins not reported 12 to interact with DYRK1A in the BioGrid protein interaction database. Given evidence of the functional 13 significance of DYRK1A in T98G cells (Di Vona et al., 2015; Litovchick et al., 2011; Litovchick et al., 2007) , our 14 new data on the DYRK1A protein-protein interaction network in human cells will serve as a resource for the 15 future functional studies of this important protein kinase. 16
Our analysis identified DCAF7 (also known as WDR68 or HAN11) as most highly enriched in the 17 DYRK1A immunoprecipitates among DYRK1A-binding proteins. Structurally, DCAF7 is a WD40-repeat protein 18 that directly binds to several protein kinases including DYRK1A, and serves as an adaptor to mediate their 19 interactions with other proteins including adenovirus E1A protein (Glenewinkel et al., 2016; Miyata and Nishida, 20 2011; Ritterhoff et al., 2010) . Some of DYRK1A interactions identified in our study could be mediated by 21 DCAF7, and further studies will be needed to characterize the role of DCAF7 in regulating the DYRK1A 22 interaction networks. Furthermore, the DCAF7-mediated interaction of DYRK1A with E1A could alter DYRK1A 23 interacting networks in HEK293T cells because of the presence of this viral protein. Indeed, while fourteen of 24 the DYRK1A-interacting proteins were detected in both T98G and 293T cells ( Figure S1A ), several of the 25 proteins known to interact with E1A including RB1, RBL1, RBL1 and EP300, were not detected in our analysis ((Varjosalo et al., 2013) and this work). In addition to its adaptor function, DCAF7 is recruited into the Cul4-1 DDB1 ubiquitin ligase complex that has been recently shown to regulate stability of DNA ligase I (LIG1), one of 2 the key enzymes in the alternative NHEJ DNA repair (Peng et al., 2016) . It remains to be determined whether 3 DYRK1A plays a role in the DCAF7-mediated degradation of LIG1 and DNA repair. Furthermore, the proteins 4 that are most enriched in the DYRK1A interactome remain to be characterized, and their functional connection 5 to DYRK1A is not apparent. Also of note, DYRK1A-interacting proteins TROAP and LZTS2 have been shown 6 to function as tumor suppressors (Cui et al., 2013; Johnson et al., 2013; Lian et al., 2017) , and it will be 7 important to determine their role in DYRK1A-mediated inhibition of cell proliferation (Litovchick et al., 2011) . 8
The complexity of the protein-protein interaction network involving DYRK1A likely reflects its diverse 9 functions in the context of specific cellular compartments or as part of different protein complexes. Here, we 10 provide functional characterization of the interaction between RNF169 and DYRK1A that revealed the role of 11 DYRK1A in the DNA damage pathway by regulating 53BP1, one of the key response factors to DNA DSB 12 lesions (Panier and Boulton, 2014). The DNA DSBs are repaired in the cell cycle-dependent manner by either 13 homologous recombination repair (HR) or the non-homologous end joining (NHEJ), and the choice of 14 appropriate repair mechanism involves multiple factors that mediate and recognize modifications of the 15 chromatin around the lesion (Hustedt and Durocher, 2016). Ubiquitin ligase RNF168 plays a key role in 16 recruitment of 53BP1 to DSB sites (Doil et al., 2009; Fradet-Turcotte et al., 2013; Panier and Boulton, 2014) . 17 RNF168 binds to RNF8-ubiquitylated histones and catalyzes H2A-K15ub modification required for the 18 recruitment of 53BP1 that protects the damaged DNA ends from excision and therefore facilitates the repair by 19 NHEJ (Doil et al., 2009; Panier and Durocher, 2009 ). RNF169 is a homolog of RNF168 and a relatively new 20 player in the DNA damage response pathway. RNF169 also recognizes H2A-K15ub marks but lacks the E3 21 ubiquitin ligase of its own, therefore its accumulation is thought to limit the recruitment of 53BP1 to DSBs 22 (Chen et al., 2012; Hu et al., 2017; Poulsen et al., 2012) . The function of RNF169 is best revealed upon its 23 overexpression when it prevents the accumulation of 53BP1 at the DSBs, resulting in increased HR-mediated 24 DNA repair efficiency due to a more efficient resection of the DNA ends (Chen et al., 2012; Poulsen et al., Our study confirms the role of RNF169 as a negative regulator of 53BP1 accumulation, and supports 1 the role of DYRK1A as an RNF169 kinase that positively regulates this activity through both direct and indirect 2 mechanisms. Previous studies found that a high-affinity ubiquitin-binding MIU domain in RNF169 is required 3 for its ability to inhibit 53BP1 accumulation at the damage sites (Chen et al., 2012; Hu et al., 2017; Poulsen et 4 al., 2012) . Our study extends this observation by demonstrating that while the binding of RNF169 to the 5 ubiquitylated histones surrounding the DSBs could be necessary, it is not sufficient to prevent the accumulation 6 of 53BP1 at the DSB sites. Indeed, the phosphorylation-deficient RNF169 mutants show reduced ability to 7 displace 53BP1 from the DSBs despite apparently normal recruitment to these sites. Interestingly, seven ATM-8 regulated phosphorylation sites in 53BP1 are required for its interaction with its key effector RIF1 but 9 dispensable for its recruitment to the damage sites (Escribano-Diaz et al., 2013; Isono et al., 2017) . It is 10 possible that DYRK1A phosphorylation of RNF169 serves to recruit an additional factor that is essential for 11 displacing 53BP1, or for stabilizing the binding of RFN169 to ubiquitylated chromatin. Constitutive presence of 12 the DYRK1A-RNF169 complex in the intact cells and after damage also indicates that another factor could be 13 recruited during DNA damage response. Further proteomic studies of the RNF169-DYRK1A complex in the 14 cells before and after DNA damage will help to identify such factor. Our analysis of DYRK1A detected 15 interaction with USP7, a ubiquitin-specific protease that has been recently shown to bind directly to RNF169 16 and to increase the stability of 53BP1, RNF169 and RNF168 (An et al., 2017; Liu et al., 2016; Yim et al., 2017; 17 Zhu et al., 2015) . Although disruption of the DYRK1A phosphorylation sites in RNF169 did not influence its 18 interaction with USP7, the role of USP7 in the DYRK1A-RNF169 mediated regulation of 53BP1 should be 19 further investigated. 20
Interestingly, while DYRK1A can facilitate the displacement of 53BP1 from DSBs by overexpressed 21 RNF169, the 53BP1 DSB recruitment defect in the DYRK1A-depleted cells appears to be, at least in part, 22 RNF169-independent. Indeed, DYRK1A-KO cell lines displayed decreased RNF169 IRIF formation, and the 23 53BP1 recruitment phenotype could not be fully rescued by RNF169 depletion in these cells. Recent studies 24
revealed that in addition to histone H2A-K15ub mark, 53BP1 recognizes and binds to H4K20Me2 mark via its 25 conserved Tudor domain, and this process is regulated by several factors including histone methyltransferases SETD8 and MMSET, as well as Polycomb proteins L3MBTL1 and JMJD2A that occupy these marks in the 1 absence of DNA damage (reviewed in (Panier and Boulton, 2014) ). Furthermore, in S/G2 phases of the cell 2 cycle, BRCA1 plays an active role in removing 53BP1 from chromatin around the damage sites using a 3 complex and not fully understand mechanism that requires CDK activity and CtIP (Chapman et al., 2012; 4 Escribano-Diaz et al., 2013; Isono et al., 2017) . Interestingly, BRCA1 was upregulated and efficiently recruited 5 to DSB sites in DYRK1A KO U-2 OS cells therefore it is possible that BRCA1-mediated eviction of 53BP1 6 could contribute to the phenotypes observed in these cells. Since BRCA1 gene expression could be regulated 7 by DYRK1A through recruitment of the DREAM repressor complex (Litovchick et al., 2011; Litovchick et al., 8 2007; Yakovlev, 2013) , the relationship between DYRK1A expression levels and the outcomes of the DNA 9 damaging therapy in cancer should be further investigated. Interestingly, loss of 53BP1 can rescue the HR 10 defects associated with inactivation of BRCA1, and could be responsible for the acquired resistance of the 11 BRCA1-mutant tumors to PARP-inhibitor therapy (Jaspers et al., 2013) . Therefore, future studies will be 12 needed to establish the exact role of DYRK1A in the context of cellular processes that regulate the recruitment 13 of 53BP1 to the DSBs, and to validate the significance of DYRK1A as a factor that can influence the outcomes 14 of cancer therapy. 15 16 17
Experimental Procedures 1

Cell lines 2
Human osteosarcoma U-2 OS, glioblastoma T98G, HEK293T and mouse NIH3T3 cells were 3 obtained from ATCC and used from early passage master stocks. Cells were regularly checked for 4 mycoplasma using in-house PCR assay and DAPI staining. T98G cells stably expressing Flag-HA epitope 5 tagged DYRK1A, GFP or DYRK1A-interacting proteins were established using pMSCV retroviral vectors and 6 puromycin selection as described in (Litovchick et al., 2011) ; this work also describes the doxycycline-inducible 7 U-2 OS cell lines expressing DYRK1A. DYRK1A-null U-2 OS and NIH3T3 cells were established using 8
GeneArt CRISPR Nuclease vector with OFP reporter (Life Technologies) harboring human or mouse DYRK1A-9 specific guide sequences. The control cell line was similarly established using a non-targeting construct 10 provided with the kit. Briefly, cells were transfected with sgRNA-CRISPR plasmids, FACS-sorted for OFP 11 expression and grown as single-cell clones that were screened for DYRK1A expression using immunoblotting. 12
Two different clones lacking DYRK1A expression were expanded and validated using antibodies against 13 different epitopes in DYRK1A as well as genomic sequencing of the nested PCR-amplified fragment 14 surrounding the sgRNA-targeted region. Human DYRK1A-specific guiding sequence for CRISPR-Cas9 15 genomic mutagenesis: top strand: 5´-tgtaaaggcatatgatcgtg-3´ and bottom strand: 5´-cacgatcatatgcctttaca-3´. 16
Nested primers for PCR amplification of DYRK1A genomic region 400 bp up-and downstream of the Cas9 17 targeting site: first PCR set: forward 5´-aagttatctgaagccttctgc-3´ and reverse 5´-catggtatgctacatggaaggc-3´; 18 second PCR set: -forward 5´-cttagggttcaggtatctctc-3´ and reverse 5´-ccaagatttagactattactac-3´). The second 19
PCR primer set was also used for sequencing of the purified PCR products. Mouse Dyrk1a-specific guiding 20 sequence for CRISPR-Cas9 genomic mutagenesis: top strand: 5'-ggacgattccagtcataaga-3', and bottom strand: reverse 5`-ggcactgactagccagaaacc-3'; second PCR primer set: forward 5'-ttgtttgggggttccttgtg-3' and reverse 5'-from the PCR with 2nd primer set were purified, cloned into Promega pGEM®-T Easy vector. Multiple DNA 1 clones were sequenced to confirm the presence of mutations and the absence of the wild type sequences. 2
Chemicals and treatments 3
To induce DNA damage, the cells were exposed to gamma irradiation using MDS Nordion Gammacell 4 40 research irradiator with a Cs 137 source (ON, Canada) or subjected to laser beam irradiation to induce DNA 5 damage as described in (Poulsen et al., 2012) . Olaparib (AZD2281, Ku-0059436 from Selleckchem, catalog 6
No. S1060) and harmine (from Sigma; catalog No. H8646) stock solutions were prepared in DMSO, and used 7 for cell treatments at 8µM or 10µM final concentrations, respectively. 8
RNAi and Plasmids 9
siRNA oligos used in this study were from Ambion/Thermo Fisher Scientific including siRNF169 10 (Silencer Select, ID: s48512, Cat# 4392420) and Negative Control No.1 siRNA (Silencer Select, Cat# 11 4390843). siRNA transfections were performed using Lipofectamine RNAiMAX (Invitrogen) according to the 12 manufacturer's instructions. GFP-tagged mouseDyrk1a wild-type and mutant constructs were a kind gift from 13 G. D'Arcangelo (Yabut et al., 2010) . HA-RNF169-pcDNA3 construct was a gift from N. Mailand (Poulsen et al., 14 2012 ). The phospho site mutants of RNF169 were generated using the QuikChange II XL site directed 15 mutagenesis kit (Agilent Technologies), and verified by sequencing. Plasmid transfections were performed 16 using either TransIT-2020 transfection reagent (Mirus Bio) or polyethylenimine reagent (Polysciences Inc) that 17 was prepared according to manufacturer's protocol. 18
MudPIT proteomic analysis 19
MudPIT proteomic analysis was performed as described in (Florens and Washburn, 2006; Litovchick et al., 20 2011; Litovchick et al., 2007) using Finnigan LTQ Linear ion trap mass spectrometer equipped with an 21 electrospray ionization source. T98G cells stably expressing DYRK1A-Flag-HA or GFP-Flag-HA (control) were 22 used for immunoprecipitations with anti-HA antibody agarose beads (clone HA7, Sigma). Proteins were eluted 23 from beads using HA peptide, concentrated and digested with trypsin. Tryptic peptides were resolved using Quaternary Agilent 1100 series HPLC and microcapillary multi-dimensional C 18 -SCX-C 18 matrix using fully 1 automated 10-step chromatography run and electrosprayed into mass spectrometer. Full MS spectra were 2 recorded on the peptides over a 400 to 1,600 m/z range, followed by five tandem mass (MS/MS) events 3 sequentially generated in a data-dependent manner on the first to fifth most intense ions selected from the full 4 MS spectrum (at 35% collision energy). SEQUEST(Eng et al., 1994) was used to match MS/MS spectra to 5 peptides in a database of 58622 amino acid sequences, consisting of 29147 Human proteins (non-redundant 6 entries from NCBI 2011-08-16 release). To estimate relative protein levels, spectral counts were normalized 7 using Normalized Spectral Abundance Factors (NSAFs) (Litovchick et al., 2007; Swanson et al., 2009; 8 Zybailov et al., 2006) . Average NSAFs were calculated from four biological replicate DYRK1A pull-down 9 experiments. 10
Kinase assays 11
For RNF169 phosphorylation assays, HEK293T cells were transfected with HA-tagged RNF169 12 constructs and lysed using RIPA buffer (50mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% Sodium 13 deoxycholate and 0.1% SDS) supplemented with phosphatase and protease inhibitor cocktails (Millipore) and 14 1:10,000 β-mercaptoethanol. Extracts were incubated with 1 µg anti-HA antibody and protein A beads 15 followed by six washes in EBC buffer (50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 120 mM NaCl and 0.5% NP-40, 16 phosphatase and protease inhibitors and 1:10,000 β-mercaptoethanol, and one final wash with kinase assay 17 buffer (Cell Signaling) containing 25 mM Tris-HCl, pH 7.5, 5 mM β-glycerophosphate, 2 mM DTT, 0.1 mM 18 Na 3 VO 4 , 10 mM MgCl 2 . The immunoprecipitated wild type or mutant RNF169 proteins were used as substrates 19 in a kinase assay reaction in the presence of 1 µM cold ATP, 5 µCi of [γ-32 P] ATP and 200 ng GST-DYRK1A 20 (Life Technologies) for 30 min at RT. The beads containing phosphorylated proteins were washed once with 21 EBC buffer and analyzed by SDS-PAGE and autoradiography. For LIN52 phosphorylation assays, extracts 22 from control and DYRK1A-KO U-2 OS cell lines (1 mg/ml) were prepared using EDTA-free EBC buffer 23 supplemented with phosphatase inhibitors, 2 mM DTT, 10 mM MgCl2, 10 mM MnCl2 and 200 µM ATP, and 24 incubated at 30°C with 6 ng GST-LIN52 in a 100 µl reaction volume. Reactions were terminated at different times by adding SDS-PAGE loading buffer and heating at 95°C for 10 min, and analyzed by WB with indicated 1 antibodies as described in (Litovchick et al., 2011) . 2
Immunofluorescence 3
Cells were seeded on glass coverslips in 6-well dishes and allowed to attach for 24 h. After washing in 4 PBS three times, cells were fixed in 4% formaldehyde for 20 min and permeabilized with 0.2% Triton X-100 in 5 PBS containing 5% BSA for 30 min followed by incubation with primary and secondary antibodies (1h at room 6 temperature). The coverslips were then mounted in Fluoroshield mounting medium with DAPI (Abcam) and 7 viewed using Zeiss Axio AX10 Imager.M1m fluorescence microscope equipped with AxioCam MRm camera. 8
Images were acquired using AxioVision, AxioVs40 (V 4.8.2.0) software. The images were analyzed using FIJI 9
software (Schindelin et al., 2012) . Briefly, images in JPEG format were processed to find the total number of 10 foci (maxima). A noise tolerance value of 20 or 30 was used, and it was the same for all samples within each 11 comparison group. For 53BP1, average foci per cell and number of cells with greater than 10 foci were 12 calculated. For HA-RNF169, average foci per HA-positive cell and number of HA-positive cells with greater 13 than 5 or 10 foci were calculated. To analyze 53BP1 in HA-RNF169 expressing cell lines, 53BP1 foci were 14 scored only in the HA-positive cells. For each biological repeat, more than 100 cells were typically processed. 15
Immunoblotting and immunoprecipitation 16
For immunoblotting, cells were lysed in EBC or RIPA buffers for 10 min at 4 °C and then centrifuged at 17 14,000g for 15 min at 4 °C. Protein concentrations were determined by DC protein assay (BioRad). Protein 18 samples were resolved using polyacrylamide gels (BioRad), transferred to nitrocellulose membrane (GE 19 Healthcare) and probed by specific antibodies as recommended by manufacturer. For immunoprecipitation, 20 cell extracts were incubated with appropriate antibodies (1 µg/ml) and Protein A Sepharose beads (GE 21 against LIN52 and phospho-S28-LIN52 were described in (Litovchick et al., 2011) . Rabbit antibodies against 1 DCAF7, FAM117B, LZTS1, LZTS2 and TROAP were custom samples provided by Bethyl. containing approximately 6 mg of protein was loaded on top of a pre-formed glycerol gradient in lysis buffer (5 8 ml, 5 -45%). The sample was then centrifuged using SW55Ti rotor at 45,000 rpm at 4°C for 18 hours, after 9 which 200 µL fractions were collected from the top of the gradient and analyzed by SDS PAGE electrophoresis 10 using Criterion gels (BioRad) and Western Blotting. 11
DSB repair Assay 12
DR-GFP reporter cell lines were established by transfecting the DR-GFP reporter construct (gift from 13
Maria Jasin, Addgene plasmid # 26475 (Pierce et al., 1999)) into the control or DYRK1A-KO U-2 OS cells 14 followed by puromycin selection as described in (Yakovlev, 2013) . The cells stably expressing the DR-GFP 15 reporter were infected with adenovirus to express I-SceI at MOI 50. To monitor the HRR efficiency, GFP 16 positive cells were detected 48hr post-infection using flow cytometry as described in (Pierce et al., 1999; 17 Yakovlev, 2013) . 18
Cell Cycle Analysis 19
U-2OS WT and DYRK1A-KO CRISPR cells were seeded in 10cm dishes at a density of 0.5X10 6 -20 1X10 6 .cells/dish. After 5Gy or 15Gy irradiation and incubation for 24hr, the cells were harvested and incubated 21 with 0.05 mg/mL propidium iodide in 3.8 mM sodium citrate buffer containing 0.1% Triton X-100 and RNAse A 22 solution (Sigma, R4642), and incubated at room temperature for 1 h. The cells (at least 10,000 per condition) 23
were then analyzed using FACS Canto II flow cytometer (Becton Dickinson, San Jose, CA, USA),
Statistical analysis and bioinformatic tools 1
For quantitation of cell-based experiments, 100 or more cells per conditions were typically scored. To calculate 2 statistical significance, data from at least three biological replicates was analyzed using two-tailed Student's t-3 test. For protein networks analysis, list of proteins detected in at least three out of four DYRK1A MudPIT 4 analyses was analyzed using MetaScape web-based software (metascape.org) that integrates data from 5
BioGrid (Chatr-Aryamontri et al., 2015) and other protein databases with custom datasets to build protein-6 protein interaction networks. To test the effect of DYRK1A expression on survival, level 3 gene expression data 7 from TCGA summarized as RSEM values was obtained using TCGA2STAT R package v 1.2, along with 8 corresponding clinical annotations. Data for breast cancer (BRCA) and lung adenocarcinoma (LUAD) cancers 9
were obtained separately. To identify if the expression of DYRK1A affects survival in any specific clinical 10 subgroup, subsets of patients annotated with specific clinical annotations were selected (e.g., "yes" or "no" in 11 the "radiation" clinical annotation). The data was log2-transformed and analyzed using Kaplan-Meyer curves 12
and Cox proportional hazard model. The expression of DYRK1A was analyzed for its effect on survival by 13 separating patients into high/low expression subgroups. A modified approach from (Mihaly et al., 2013) was 14 used to estimate the gene expression cutoff that best separates high/low expression subgroups with differential 15 survival. Doil, C., Mailand, N., Bekker-Jensen, S., Menard, P., Larsen, D.H., Pepperkok, R., Ellenberg, J., Panier, S., 1 Durocher, D., Bartek, J., et al. (2009) . RNF168 binds and amplifies ubiquitin conjugates on damaged 2 chromosomes to allow accumulation of repair proteins. Cell 136, 435-446. 3 Durocher, D., and Pelletier, L. (2016) . 53BP1 Goes Back to Its p53 Roots. Mol Cell 64, 3-4. 4 Eng, J., McCormack, A.L., and Yates, J.R., III (1994) . An approach to correlate tandem mass spectral data of 5 peptides with amino acid sequences in a protein database. J. Amer. Mass Spectrom. 5, 976-989. Glenewinkel, F., Cohen, M.J., King, C.R., Kaspar, S., Bamberg-Lemper, S., Mymryk, J.S., and Becker, W. 18 (2016) . The adaptor protein DCAF7 mediates the interaction of the adenovirus E1A oncoprotein with the 19 protein kinases DYRK1A and HIPK2. Scientific reports 6, 28241. 20
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